Clinicians at the recent ASCO noted that more practical and accurate molecular diagnostics are approaching the clinic alongside novel targeted drug regimens.
Researchers from the US and Italy identified relapse-related methylation profiles in diffuse large B-cell lymphoma tumors taken at diagnosis and relapse.
The method could potentially be useful as a companion diagnostic for targeted drug therapies.
The results need to be validated but demonstrate the clinical utility of a more sensitive screen for detecting minimal residual disease.
In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.
In PNAS this week: microRNA catalogue, early mutational events in follicular lymphoma, and more.
The assay could be useful for identifying patients unlikely to respond to therapy and provide an alternative for monitoring therapy response.
Diagnovus has developed a suite of oncology and gastroenterology tests using PCR, next-generation sequencing, and gene expression analysis.
The decision opens up the largest market in the country to the firm's lymphoma and leukemia testing services.
HTG plans to list its shares on the Nasdaq and is the 11th firm this year in the MDx/omics tools space to either go public or file for an IPO.
Researchers have sequenced the genome of the depth-dwelling giant squid.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.
Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.
In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.